Investigational antibody fragment to target FcRn: active idiopathic inflammatory myopathy treatment
Client: Immunology company
Services: Translation and Localization
Language pair: English into Portuguese
Volume: 200,000 words
Translation Memories and Quality Control technologies: memoQ and Xbench
I have been helping a global immunology company expand to Brazilian population their phase 2/3 clinical trial to evaluate their first experimental medicine for active idiopathic inflammatory myopathy.
One of the world’s leading Clinical Research Organizations (CROs) — founded in Dublin, Ireland (1990) —, that provides consulting and outsourced development and commercialization services to Pharmaceutical, Biotechnology, Medical device and Government and Public Health organizations.
In collaboration, a global immunology company — located in Ghent (Belgium), Boston, Massachusetts (USA) and Tokyo (Japan) — that is currently developing their first experimental medicine (a first-in-class investigational antibody fragment to target the neonatal Fc receptor, FcRn).
The medicine is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG, autoantibodies, including myasthenia gravis, pemphigus vulgaris, immune thrombocytopenia, active idiopathic inflammatory myopathy and chronic inflammatory demyelinating polyneuropathy.